List of Excipients in Branded Drug UNITUXIN

« Back to Dashboard

Unituxin Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Unituxin, the brand name for dinutuximab, is an intravenous anti-GD2 monoclonal antibody for pediatric patients with high-risk neuroblastoma. Its commercial formulation uses a conventional biologic excipient system: histidine, glycine, polysorbate 80, and water for injection. The main commercial opportunities are not commodity excipient replacement in the existing product. They are biosimilar formulation development, polysorbate-stability solutions, low-volume pediatric delivery, container-closure optimization, and manufacturing platforms that reduce aggregation and product loss.

What excipients are used in the Unituxin formulation?

The FDA-approved Unituxin formulation is supplied as a single-dose 5 mL vial containing 17.5 mg of dinutuximab, equivalent to 3.5 mg/mL. The listed inactive ingredients are histidine, glycine, polysorbate 80, and water for injection. The product has a target pH of approximately 6.8.[1]

Formulation component	Function in Unituxin	Commercial significance
Histidine	Buffering agent	Controls pH during storage and administration
Glycine	Stabilizing amino acid and tonicity-supporting excipient	Can reduce protein-protein interactions and aggregation
Polysorbate 80	Surfactant	Limits adsorption to vial, tubing, and infusion equipment
Water for injection	Vehicle	Supports the liquid drug product
Dinutuximab	Anti-GD2 IgG1 monoclonal antibody	Active biological ingredient

The product is refrigerated and administered after dilution for intravenous infusion. Unituxin is not a lyophilized product, so commercial value is concentrated in liquid-state stability, surfactant control, container compatibility, and cold-chain performance.

What is the excipient strategy for dinutuximab?

The Unituxin formulation follows a standard antibody stabilization strategy based on four requirements:

1. Maintain a pH compatible with dinutuximab stability.
2. Limit aggregation during refrigerated storage.
3. Prevent adsorption to primary packaging and infusion-contact surfaces.
4. Preserve potency after dilution and during the infusion period.

Histidine provides buffering near the formulation pH. Glycine is frequently used in antibody products as a stabilizing amino acid and can reduce unfavorable protein interactions. Polysorbate 80 protects against interfacial stress caused by agitation, air-liquid interfaces, pumps, bags, and infusion tubing.

The formulation has a relatively straightforward excipient profile. That simplicity can reduce manufacturing complexity, but it also limits the ability to create a broad composition-of-matter patent position based only on the disclosed ingredients. A follow-on developer would likely need to establish a material improvement in stability, aggregation, oxidation, subvisible particles, vial adsorption, or administration compatibility.

What formulation risks matter most?

The principal risks are:

• Polysorbate 80 hydrolysis and oxidation.
• Protein aggregation during shipment or infusion.
• Formation of subvisible particles.
• Loss of potency after dilution.
• Adsorption to low-binding tubing and infusion bags.
• Extractables and leachables from single-use systems.
• Variability in excipient purity and peroxide levels.
• Freeze-thaw or temperature-excursion damage.
• Product loss caused by the small pediatric dose and vial overfill requirements.

Polysorbate degradation is especially important. Hydrolysis can generate free fatty acids, which may contribute to particles or interact with the antibody. Oxidative degradation can produce species that affect protein oxidation and product quality. A commercial excipient strategy should therefore control polysorbate grade, peroxide content, fatty-acid distribution, storage conditions, and supplier change management.

What formulation patents could protect a Unituxin follow-on product?

A follow-on formulation could seek protection in several technical areas:

Patent target	Potential claim scope	Strength of commercial position
Excipient combination	Dinutuximab or an anti-GD2 antibody with a defined histidine, glycine, and surfactant range	Moderate if supported by comparative stability data
Surfactant substitution	Polysorbate 20, poloxamer 188, or another surfactant replacing polysorbate 80	Moderate, but requires proof of improved performance
Low-concentration formulation	Lower antibody concentration with reduced viscosity or improved stability	Limited unless a specific technical effect is demonstrated
High-concentration formulation	Concentrated product enabling lower infusion volume	Potentially strong if pediatric administration improves
Lyophilized formulation	Freeze-dried dinutuximab with a defined bulking and stabilizing system	Potentially strong, but development cost is higher
Container system	Low-binding vial, syringe, bag, or tubing configuration	Narrow but commercially useful
Dilution stability	Defined hold time and concentration range after dilution	Useful for hospital handling and pharmacy operations
Manufacturing process	Controlled mixing, filtration, filling, or surfactant addition sequence	Potentially important if process-sensitive impurities are reduced
Combination delivery	Dinutuximab with a specified infusion protocol or premedication system	More likely to support method-of-use protection than composition protection

A patent based solely on known excipients may face novelty and obviousness challenges. Stronger claims would link the excipient system to a measurable result, such as reduced high-molecular-weight species, lower particle formation, improved potency after dilution, or a defined shelf-life extension.

When does Unituxin lose regulatory exclusivity?

Unituxin was approved by the FDA on March 10, 2015, under Biologics License Application 125516. The product received orphan-drug designation for high-risk neuroblastoma and pediatric regulatory benefits.[1,2]

Regulatory protection	Relevant date or period	Commercial effect
FDA approval	March 10, 2015	Product entered the U.S. market
Orphan-drug exclusivity	Approximately seven years from approval	Protected the approved orphan indication against certain competing approvals
BPCIA reference-product data exclusivity	12 years from first licensure	Reference-product exclusivity runs to approximately March 10, 2027
Pediatric exclusivity	Depends on FDA grant and applicable studies	Can add six months to qualifying exclusivity periods
Patent protection	Patent-specific	Must be evaluated through USPTO and litigation records

The 12-year biologic data-exclusivity period is separate from patent term. After the statutory exclusivity period expires, a biosimilar applicant may pursue a section 351(k) application, subject to FDA requirements and any enforceable patent rights.

What is the Orange Book and Purple Book status of Unituxin?

Unituxin is a biologic, so its central U.S. reference-product listing is in the FDA Purple Book rather than the Orange Book. The Orange Book primarily covers approved small-molecule drugs and listed drug patents. Biologic patent and interchangeability analysis follows the Public Health Service Act and the Biologics Price Competition and Innovation Act.[3,4]

Unituxin’s commercial patent analysis should therefore separate:

• FDA reference-product and licensure information.
• USPTO patent records.
• Patent assignments and ownership.
• BPCIA patent-listing and notice-of-commercial-marketing activity.
• District-court or Federal Circuit litigation.
• State substitution consequences, if an interchangeable biosimilar is approved.

A conventional Orange Book Paragraph IV strategy does not directly apply to Unituxin in the same manner as it applies to an ANDA drug. A biosimilar applicant would instead use the BPCIA pathway and address relevant patents through the statutory patent-exchange process or litigation.

Which companies compete with Unituxin?

Unituxin competes within the anti-GD2 neuroblastoma market rather than against conventional generic drugs.

Product	Active ingredient	Sponsor or manufacturer	Modality	Key market distinction
Unituxin	Dinutuximab	United Therapeutics	Anti-GD2 monoclonal antibody	U.S. pediatric high-risk neuroblastoma product
Qarziba	Dinutuximab beta	Recordati, historically developed by Apeiron	Anti-GD2 monoclonal antibody	European product with different regulatory and formulation history
Danyelza	Naxitamab-gqgk	Y-mAbs Therapeutics	Anti-GD2 monoclonal antibody	U.S. accelerated approval for relapsed or refractory high-risk neuroblastoma

Dinutuximab and dinutuximab beta are not automatically interchangeable. Differences may include antibody sequence, glycosylation, dosing schedule, infusion duration, excipient composition, manufacturing process, and clinical evidence. A biosimilar developer targeting Unituxin would need to demonstrate high similarity to dinutuximab, not merely clinical similarity to another anti-GD2 antibody.

What commercial opportunities exist for Unituxin excipients?

Polysorbate 80 quality and supply

Specialty suppliers can create value through low-peroxide, low-impurity polysorbate 80 grades supported by lot-release data and extended stability packages. Supply agreements may include oxidation testing, hydrolysis monitoring, fatty-acid profiling, and change-control commitments.

A supplier with validated performance in antibody formulations can compete on total cost of quality rather than price per kilogram. For a low-volume pediatric biologic, reducing batch failure, particle excursions, and vial rejection can be more valuable than reducing excipient unit cost.

Polysorbate alternatives

Polysorbate 20, poloxamer 188, and newer surfactant systems may support a reformulated dinutuximab product. The opportunity is strongest if an alternative reduces oxidation, particle formation, or infusion-contact loss.

The commercial barrier is comparability. A surfactant change can affect aggregation, potency, immunogenicity risk, and container interaction. A new formulation may require substantial analytical and clinical bridging, particularly if it changes exposure, infusion tolerability, or dosing convenience.

Pediatric low-volume delivery

Unituxin is administered to children, where infusion duration, fluid volume, and pharmacy preparation burden have direct commercial relevance. A concentrated formulation or optimized dilution protocol could reduce:

• Infusion-bag volume.
• Nursing time.
• Drug waste.
• Exposure to tubing and bag surfaces.
• Pharmacy compounding steps.
• Total chair time.

A concentration increase would require careful evaluation of viscosity, osmolality, infusion rate, local tolerability, and dosing accuracy. A ready-to-dilute or ready-to-use presentation could support a strong hospital value proposition even without changing the active ingredient.

Lyophilized presentations

A lyophilized dinutuximab product could reduce dependence on refrigerated liquid stability and improve shipping resilience. The tradeoff is higher manufacturing complexity, reconstitution time, potential protein damage during freezing and drying, and the need for a new container and reconstitution system.

The strongest lyophilization opportunity would combine longer room-temperature excursion tolerance with reduced aggregation and a practical pediatric reconstitution volume.

Container-closure and administration systems

Low-binding vials, silicone-reduced syringes, infusion bags, and tubing systems can protect product recovery. A device or administration patent may have greater practical value than a narrow excipient patent if it reduces drug loss and standardizes hospital use.

Potential claim areas include:

• Defined antibody recovery after infusion.
• Low-binding contact materials.
• Specified tubing dwell time.
• Compatibility with saline or dextrose dilution.
• Reduced particle formation during pumping.
• Closed-system transfer for pharmacy preparation.

How strong is the Unituxin patent estate?

The commercial strength of the estate depends on three separate elements: remaining patent term, claim breadth, and the existence of technically differentiated formulation or manufacturing claims.

The disclosed histidine-glycine-polysorbate formulation is a relatively conventional antibody platform. Its defensive value is therefore likely lower than that of a narrowly defined process or stability claim supported by comparative data. A follow-on company should prioritize freedom-to-operate analysis around:

• Composition patents covering dinutuximab or anti-GD2 antibodies.
• Glycosylation and cell-line patents.
• Antibody sequence and humanization claims.
• Manufacturing and purification processes.
• Formulation and stability claims.
• Dosing and infusion methods.
• Device and container claims.

Method-of-use patents may be more commercially important than excipient claims if they cover a specific neuroblastoma treatment regimen, maintenance schedule, combination therapy, or patient subgroup. Such claims can affect biosimilar labeling and launch strategy even when the formulation is not separately protected.

What generic or biosimilar launch risks exist for Unituxin?

The principal launch risks are regulatory and development-related rather than conventional ANDA substitution risk.

A biosimilar developer would need to manage:

1. Reference-product exclusivity through approximately March 2027.
2. Analytical similarity for a complex antibody.
3. Differences in glycosylation, aggregation, charge variants, and potency.
4. Clinical and pharmacokinetic requirements.
5. BPCIA patent procedures.
6. Limited patient population for clinical enrollment.
7. Hospital adoption and oncology-center protocols.
8. Reimbursement and contracting.
9. Pharmacovigilance and immunogenicity monitoring.
10. Potential labeling limitations for protected indications.

The small pediatric neuroblastoma market can make development economically difficult. At the same time, the product’s specialized indication, high treatment value, and limited number of competitors may support premium pricing for a reliable biosimilar or improved formulation.

What licensing opportunities are available?

Licensing opportunities are most credible in four areas:

• A validated dinutuximab biosimilar with a differentiated excipient system.
• A polysorbate-stabilized antibody platform with demonstrated low-particle performance.
• A concentrated or ready-to-use pediatric infusion product.
• A manufacturing process that improves yield, recovery, or cold-chain resilience.

An excipient supplier seeking a deal with a biosimilar developer should offer more than raw material supply. The stronger package includes formulation screening, analytical methods, stability-indicating assays, regulatory documentation, change-control support, and reserve manufacturing capacity.

For the originator or licensee, formulation improvement may extend product competitiveness after core regulatory exclusivity expires. The value is highest when the reformulation reduces infusion burden or provides a clear hospital economic benefit.

Key Takeaways

• Unituxin uses histidine, glycine, polysorbate 80, and water for injection in a 3.5 mg/mL liquid formulation.
• Polysorbate degradation, aggregation, particles, and container adsorption are the leading excipient-related technical risks.
• A conventional excipient combination alone is unlikely to create a strong standalone patent position without unexpected stability or performance data.
• The 12-year U.S. biologic data-exclusivity period runs approximately to March 10, 2027, subject to applicable statutory extensions.
• Unituxin is evaluated through the Purple Book and BPCIA framework, not a conventional Orange Book Paragraph IV pathway.
• The best commercial opportunities are biosimilar formulation, concentrated pediatric delivery, low-binding administration systems, and improved polysorbate quality.
• Danyelza and Qarziba are competitive anti-GD2 products but are not automatically interchangeable with Unituxin.
• A successful follow-on product must address development cost, limited patient population, patent procedures, and hospital adoption.

FAQs

Can polysorbate 80 be removed from a Unituxin biosimilar?

Possibly, but removal would require evidence that the antibody remains stable against agitation, interfaces, dilution, filtration, shipping, and infusion-contact surfaces. A surfactant-free product would likely require a distinct formulation development and comparability strategy.

Would a Unituxin biosimilar automatically be interchangeable?

No. Biosimilarity and interchangeability are separate FDA determinations. An interchangeable designation requires additional evidence under the applicable FDA standard and may affect pharmacy substitution under state law.

Is a concentrated dinutuximab formulation commercially attractive?

Yes, if it reduces infusion volume, preparation time, drug waste, or administration burden without increasing viscosity, aggregation, infusion reactions, or dosing errors.

Could a ready-to-use Unituxin presentation receive new patent protection?

Potentially. Patentability would depend on novelty, non-obviousness, and claim support for the specific container, concentration, dilution state, stability profile, or administration system.

Does Qarziba create direct biosimilar precedent for Unituxin?

No. Qarziba may provide technical and clinical information about anti-GD2 antibody development, but a Unituxin biosimilar must establish similarity to dinutuximab, including its molecular and manufacturing attributes.

References

1. U.S. Food and Drug Administration. (2022). Unituxin (dinutuximab) prescribing information. United Therapeutics Corporation.

2. U.S. Food and Drug Administration. (2015, March 10). FDA approves first therapy for high-risk neuroblastoma. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

4. U.S. Food and Drug Administration. (2021). Questions and answers on biosimilar development and the BPCI Act. https://www.fda.gov

5. U.S. Pharmacopeia. (2024). General chapter <1043>: Ancillary materials for cell, gene, and tissue-engineered products. United States Pharmacopeial Convention.